Interferon inducers were used against vaccinial encephalitis to study the targetorgan treatment of neurotropic disease and to correlate interferon levels and the antiviral state following such treatment. A 45-,ug amount of statolon, 30 Mg of polyribinosinic-polyribocytidylic acid complex (poly I. poly C), or 0.0154 HA unit of Sendai virus given intracerebrally protected 100% of mice challenged the next day with 1,000 median lethal doses (LD50) of vaccinia virus. Significant protection against 1,000 LD50 of vaccinia virus persisted for 1, 4, or 3 weeks after poly I -poly C, statolon, or Sendai virus (154 HA units), respectively. These doses of poly I. poly C and statolon were also used to study postinfection treatment. Mice challenged with 1, 10, 100, or 1,000 LD50 were treated intracerebrally with poly I -poly C or statolon 24 or 48 hr later. Significant increases in survival time were seen in mice challenged with 1 to 100 LD50 of vaccinia virus and treated 24 hr later. At challenges of 10 or 100 LD50, statolon was more effective than poly I -poly C in increasing survival times. When treatment was delayed until 48 hr after infection, significant increases in survival time occurred only when the challenges were in the range of 1 to 10 LD50, with poly I. poly C and statolon being equally effective. Interferon was measured by Finter's dye-uptake method, with L-929 cells and Semliki Forest virus. Poly I poly C, statolon, or Sendai virus, given intracerebrally to mice, produced serum interferon peaks of 5,120 units/ml at 2 hr, 2,560 units/ml at 12 hr, or 320 units/ml at 18 hr, respectively. Corresponding brain interfer)bn peaks were 640 units/g at 2 hr, 640 units/g at 4 to 24 hr, and 960 units/g at 72 hr.
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Recent studies on interferon (IF) and host antiviral resistance have involved direct administration of interferon inducers to the organ most immediately affected, such as the eyes in viral keratitis (18) or the lungs in viral pneumonitis (12, 16) . Application of target-organ treatment to the central nervous system has been relatively unexploited. In an earlier study of IF and viral encephalitis (9) , where both peripheral viral challenge and treatment routes were employed, significant protection occurred only when circulating IF preceded viremia. In other work (4), two peripheral injections of polyriboinosinicpolyribocytidylic acid complex (poly I poly C), at 300,g per 20-g mouse, prior to the onset of encephalitis symptoms, increased the survival of mice intranasally inoculated with one median lethal dose (LD50) of vesicular stomatitis virus.
In experiments where virus challenge was directly into the brain (1, 3) and Sendai virus, supplied by E. Minuse of this laboratory. The Sendai virus was used as infected allantoic fluid, stored at -70 C, with sorbitol added for stability. The virus preparation used was nonpathogenic given ic, but had a hemagglutinating titer of 512 units/mi.
Viruses Sample preparation. Blood was collected from ether-anesthetized mice by cardiac puncture by the method of Falabella (6) . Blood samples were pooled from three mice; serum was separated from cells and stored at -20 C. After bleeding, brains of the same three mice were removed aseptically, ground with alundum, and diluted to 25 ' in a balanced salt solution. After standing at 4 C for 6 to 24 hr, the brain suspensions were centrifuged to remove cellular debris, and the supernatant fluid was stored at -20 C. When mice had been injected with Sendai virus, the brain samples were diluted in 0.1 M tartaric acid to give a pH of 3, and the samples were kept at 4 C for 48 To observe the duration of the antiviral status resulting from these inducers, mice were challenged ic with vaccinia virus at various intervals after the ic injection of 30,Mg of poly I -poly C, 45 Mg of statolon, or 1.54 HA units of Sendai virus. For poly I poly C and statolon, these were the lowest doses that had protected all the mice when given as a single, 24-hr prophylactic dose. An effective antiviral state, measured against this significant challenge, existed 1 week after poly I -poly C, 4 weeks after statolon, and 3 weeks after Sendai virus (Table 2) . Therapeutic, i.e., postinfection, treatment was also examined. Groups of mice were inoculated ic with vaccinia virus representing challenges of 1 to 1,000 LD,0, and 24 or 48 hr later were treated with poly I -poly C or statolon ( mating the ic minimal 100% protective doses were ineffective given intraperitoneally. The serum IF curves after intracerebral stimulation ( Fig. 1 ) resemble those reported to follow intravenous injection of inducers (25, 26) . This might be expected, since Field (7) and Mims (17) reported that material injected ic in mice is immediately taken up into the cerebrospinal fluid and then passes into the circulation. Consequently, ic injection of IF inducers could exert peripheral as well as local effects. The response of brain IF (Fig. 1) is also similar to that seen after intravenous stimulation. The later peak in brain due to Sendai virus may indicate stimulation by newly replicated, endogenous but nonpathogenic virus, whereas the prompt response in serum may be stimulation by the exogenous viral input. The time of occurrence of IF in brain after Sendai virus (Fig. 1) is similar to that following the ic inoculation of Semliki Forest or West Nile viruses (8) . The similarity in peak levels after the various inducers may explain the similar effectiveness of poly I. poly C and statolon when their administration was delayed to 48 hr after infection (Table  3) . At 24 hr postinfection, statolon was the more effective. At an advanced stage of disease, such as 48 hr postinfection, the magnitude of the response to treatment may be as important as duration. It is of interest that low concentrations of inducers were effective against vaccinia virus ic. Hilleman (13) suggested that low concentrations of inducers might leave some cells unstimulated and capable of response at a later time. Low doses, therefore, should not only minimize toxicity but might also be less likely to produce hyporeactivity.
When one considers approximately equipotent doses of statolon and poly I -poly C, the longer duration of protection from statolon or Sendai virus, compared to poly I -poly C (Table 2) , may reflect the greater ability of a virion (5) to survive than a naked ribonucleic acid, such as poly I. poly C. These data do not delimit the total duration of the protective effect of statolon ic. Statolon and pyran copolymer (21) produced protection against MM virus for 30 or more days when the challenge dose of virus was approximately one LD50. In the present study, the high level of protection at the longest interval tested suggests that the period of effectiveness of statolon, given ic, extends well beyond 4 weeks. Sendai virus-induced protection declined to a minimal level of significance, survival index of 1.5, at 3 weeks. It has been claimed (2, 20) that interferon is the probable mechanism through which inducers provide protection; others (4, 14, 15, 22, 24) 
